Non-alcoholic Steatohepatitis (NASH) - Global Strategic Business Report

The global market for Non-alcoholic Steatohepatitis (NASH) is estimated at US$7.4 Billion in 2023 and is projected to reach US$160.7 Billion by 2030, growing at a CAGR of 55.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Vitamin E & Pioglitazone Drugs segment, which is expected to reach US$53.4 Billion by 2030 with a CAGR of a 45.4%. The Obeticholic Acid (OCA) Drugs segment is also set to grow at 43.5% CAGR over the next 7 years.
• Regional Analysis: Gain insights into the U.S. market, estimated at $2.5 Billion in 2023, and China, forecasted to grow at an impressive 51.8% CAGR to reach $24 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Non-alcoholic Steatohepatitis (NASH) Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-alcoholic Steatohepatitis (NASH) Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Non-alcoholic Steatohepatitis (NASH) Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as AstraZeneca PLC, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 12 Featured):

• AstraZeneca PLC
• Conatus Pharmaceuticals Inc.
• Galmed Pharmaceuticals Ltd.
• Genfit SA
• Gilead Sciences, Inc.
• Immuron Ltd.
• Intercept Pharmaceuticals, Inc.
• Zydus Cadila

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.